Alarming results and some good news from MDR and IVDR survey of notified bodies
31 Jul 2023
By Annette Van Raamsdonk and Evangeline Loh, Emergo by UL
The European Commission (EC) posted a July 25 update on the current state of Medical Devices Regulation (2017/745 MDR) and In Vitro Diagnostics Devices Regulation (2017/746 IVDR) applications.
The data collected was from a recent survey instrument intended to monitor and analyze the availability of devices on the EU market.
Study on medical devices and Notified Body survey instrument
The study was led by Gesundheit Österreich GmbH (Austrian National Public Health Institute) with Areté and Civic Consulting. The study started in December 2022 and will end in 2025.
The survey instrument to collect the most recent data on certificates issued and the number of applications received was shared with the Notified Bodies on April 3, 2023, and concluded May 5, 2023.
The collected data have been compared with data compiled by the EC between February 2021 and October 2022.
Survey respondents
All Notified Bodies responded, resulting in a 100% response rate. This consists of 38 Notified Bodies designated to the MDR and 10 Notified Bodies designated to the IVDR. Of these 39 Notified Bodies, nine are designated to both the MDR and IVDR, 28 Notified Bodies are designated to the MDR only, and one Notified Body is designated to the IVDR only.
General survey results
The data (March 2023) reports 11,418 MDR applications and 2,951 MDR certificates, compared to the 23,156 MDD and AIMDD that were still valid at the same time. The number of MDR applications and issued MDR certificates has been steadily increasing.
The data is reported as QMS applications and certificates, Annex IX Chapter I or Annex XI Part A, or MDR Product Applications and Certificates, Annex IX Chapter II, Annex X or Annex XI Part B according to MDR (which can be compared with Annex II, including section 4 MDD). We would relate this as the conformity assessment routes for Class IIb to Class I measuring, sterile, and reusable surgical instruments or the conformity assessment route for Class III medical devices.
For Class IIb and lower risk, there have been 7,551 MDR applications and 1,954 MDR certificates. For Class III, there were 3,867 MDR applications and only 997 MDR certificates.
Results for the IVDR are similarly low. Only 950 applications have been received, and 331 IVDR certificates have been issued. And this is with over 80% of self-certified IVDD devices that will need Notified Body involvement under the IVDR: there were 1,551 valid IVDD certificates (October 2022).
Some alarming results
It would appear that the percentage of incomplete MDR applications has been increasing, as well as the time to receive the MDR certificate, with March 2023 compared to October 2022. In particular, for the MDR QMS and product certificates, for 86% of the certificates, the time required was greater than 13 months.
The IVDR application refusal data show that manufacturers appear to struggle with their applications. Reasons for refusal are incomplete data, wrong qualification and/or classification, and other reasons. The time it takes to get an IVDR QMS and product certificate issued in 60% of the cases is 13-18 months and 19-24 months in 30% of the cases.
Read more — including some good news for certain manufacturers — at the Emergo Group’s blog.
How to submit a contribution to MDO
The opinions expressed in this blog post are the author’s only and do not necessarily reflect those of Medical Design & Outsourcing or its employees.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.